Founded in 2018 as a biotech R&D enterprise, Onconetix pivoted significantly in late 2023 by acquiring Proteomedix and inheriting Proclarix, a CE-marked prostate cancer diagnostic test. Concurrently, it discontinued ENTADFI commercialization due to resource constraints. Despite this promising technological repositioning aimed at reducing unnecessary biopsies through protein biomarker testing, Onconetix’s revenues collapsed roughly 68% from 2024 to 2025, with mounting operating and net losses exceeding $14 million annually. The company relies heavily on external manufacturing and marketing partnerships, including a key U.S. license to LabCorp. Liquidity remains precarious with working capital deficits and ongoing reliance on PIPE financings, casting substantial doubt on its going concern status. Competitive pressures from liquid biopsy and imaging diagnostics intensify market challenges. Future prospects hinge on successful Proclarix commercialization, regulatory navigation, and securing additional capital to sustain operations.